Penny Pick Elite
During the recession, while most investors were panicking as almost every stock was tanking…I was calmly sitting at my desk with a smile on my face.
You see, while everyone around me – colleagues, friends, neighbors – were losing their shirts, I was still making money.
But I wasn’t doing it with shares of Wal-Mart stock…or bonds…or CDs.
Instead, I was using one of the most misunderstood investment tactics in the world to rake in gains that 99% of investors sidestep on a daily basis.
In fact, this technique is so profitable that the U.S. government considered banning it all together.
For those of us who know about it and know how to use it properly, though, there’s literally no limit to how much money we can make.
In fact, over the course of my research, I’ve discovered a small ring of people who’ve used this technique successfully for years to amass millions upon millions of dollars…
This is the same technique that we use for our recommendations in Penny Pick Elite. Click the Penny Pick Elite logo on the left to become a member…
Penny Pick Elite
Coming of Age With Cardiome Pharma
Development-stage pharmaceutical companies are among the riskiest equities to trade. While their product candidates may possess giant marketplace potential, bringing those products to market can be a very slippery, expensive and time-consuming slope. If and when one of those products does make it to market, however, shares of the company often take flight in dizzying fashion. Recently that has been the case with shares of Cardiome Pharma (CRME), and this issue may have even more outsized gains ahead of it in the weeks and months to come.
Cardiome Pharma Corp. is a research-based biopharmaceutical company focused on the discovery, development and commercialization of new therapies. It has one product, BRINAVESS (vernakalant IV), approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The company’s clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia or abnormal rhythm of the upper chambers of the heart. Cardiome also has several pre-clinical projects directed at various therapeutic indications.
Earlier this month, CRME shares caught fire after the company announced completion of the transfer of commercialization responsibility for BRINAVESS in the European Union (EU) from its former partner, Merck Sharp & Dohme Corp., a subsidiary of pharma heavyweight Merck & Co. As a result, Cardiome has begun supplying BRINAVESS under its own trade dress and transfer of the post-marketing study for BRINAVESS is now complete. Cardiome will continue to market BRINAVESS through its direct sales force in key European markets and through distribution partnerships in others, and recognize revenues for the product worldwide.
“The completion of the transfer of commercialization responsibility to Cardiome today is an exciting and transformational turning point in the company’s history,” said William Hunter, M.D., Cardiome’s chief executive officer. “We have taken BRINAVESS from our research lab, moved it forward through clinical development, and now we have the responsibility for commercialization of the drug in order to provide patients suffering from atrial fibrillation a rapid and convenient treatment option to restore normal sinus rhythm. We thank Merck for its cooperation over the past year in the transfer of the BRINAVESS commercialization responsibilities back to Cardiome.”
More good news for the company soon followed. On September 23rd the company announced the publication of positive data from an open label study in patients with atrial fibrillation that compared treatment with vernakalant intravenous (IV) to oral propafenone and oral flecainide—two of the most commonly used drugs on the market that treat atrial fibrillation. The study showed that patients treated with vernakalant achieved conversion to normal sinus rhythm in a median time of 12 minutes compared to 151 minutes for the propafenone group and 162 minutes for the flecainide group. These results appeared in the current issue of the Journal of Atrial Fibrillation, a peer reviewed medical journal, and represents the first study to compare these three agents.
Even more good news flowed from the company in the wake of these impressive study results. On September 24th the company announced that its subsidiary, Cardiome Development AG, had entered into an agreement with LifePharma (Z.A.M) Ltd., to sell and distribute exclusively in Cyprus.…
One More For The Road with Montalvo Spirits (TQLA)
Last month I brought your attention to a new over-the-counter issue called Montalvo Spirits (TQLA). At the time, I noted that all stocks must start somewhere, and while newly traded over-the-counter plays like Montalvo rarely get the level of attention garnered by institutionally-backed issues, the company’s shares were attracting a notable level of trading volume. Since then, TQLA has managed to tack on a dime, weathering extremely volatile market conditions, closing at $0.91 per share in recent dealings, and is currently knocking on the door of new 52-week highs.
To refresh your memory, Montalvo Spirits, Inc. develops, markets and distributes premium alcoholic beverages, with its initial offering being the award-winning Montalvo Tequila. That product was launched in April 2012, with distribution deals in New York and California. Montalvo’s Plata varietal became a finalist at the prestigious Ultimate Spirits Challenge 2013, garnering a 93 rating out of a possible 100, and at the 2013 Spirits of the Americas Competition, Montalvo’s Reposado was named “Best of Class” in the Reposado Tequila category. In addition to Tequila, the company is focused on other artisanal spirit brands with a tradition of excellence and quality.
At the time of my original alert, Montalvo had confirmed that it was launching its first widespread ad campaign in the Robb Report, a well-known luxury-lifestyle magazine featuring products — including automobiles, real estate and watches — for affluent connoisseurs. The company was also in talks to further expand distribution throughout the United States and internationally, and had just landed a key placement of its products at Disney’s Epcot’s Mexican Pavilion in Orlando.
Several corporate developments have kept Montalvo shares in the spotlight since then. In early June, the company announced that it had entered into a Letter of Intent with Broken Heart Spirits Limited, a New Zealand-based company that produces a line of craft spirits including Broken Heart Gin, for the exclusive right to sell Broken Heart Gin in the United States. The company expects to enter into an Exclusive Master Distribution Agreement with Broken Heart following the approval of Broken Heart Gin‘s formula and labels by the U.S. Tax and Trade Bureau, and hopes to launch the brand in the United States in the fall of this year.
One week later Montalvo announced the formation of a newly established Advisory Board to assist management in developing distribution and operational strategies, and to help the company identify potential portfolio brands. The company plans to appoint and introduce the initial members of the Advisory Board in the upcoming weeks. According to the company, the Advisory Board will consist of respected members of the wine and spirits industry.
Finally, on Tuesday, Montalvo announced that it was on track to meet some of its expansion plans, having recently secured distribution in the states of Connecticut and Oregon. To continue its expansion into the Northeast, the company has registered the brand with the State of Connecticut and has appointed a distributor throughout the state, with plans to launch Montalvo Tequila in Connecticut on August 1st.…
In Search Of A Good Hair Day (BLGX)
We’re all familiar with bad hair days—when you wake up on the wrong side of the bed, and nothing seems to go your way. Today I want to bring your attention to a publically-traded company that is focused on bringing people good hair days—with a hair loss prevention product that has shown promising trial results internationally, and is already penetrating markets outside of the United States. Its name is Biologix Hair, and it trades over-the-counter under the symbol BLGX.
Biologix Hair, Inc., which was acquired by T&G Apothecary Inc. in December, 2012, together with its subsidiaries, develops and manufactures Biologix Hair Therapy System—a compound and delivery system to treat follicle nutrient deficiency syndrome (FNDS). Its Biologix Hair Therapy System includes Biologix Revive, a hair formula administered as a series of shallow injections using a needle targeting the follicles starved by FNDS. The Revive formula is applied by Certified Biologix Hair Therapists through a network of Biologix Hair Therapy Centers.
Before discussing the company’s current initiatives to expand the footprint of its lead product, it’s worthwhile to take note of just how big the hair restoration market is. According to the International Society for Hair Loss Surgery, consumers worldwide spend about $2 billion on surgical hair restoration alone. IbisWorld, an independent market research firm, reports that non-surgical alternatives like Propecia and Minoxidil are part of a $7 billion per annum industry.
Biologix Hair has been tapping into that market since 2004. According to a company statement released last week, over the past 8 years more than 30,000 pre-clinical-trial treatments of Biologix Revive have been administered to more than 5000 patients in South America. Some of those patients were suffering with varying degrees of alopecia, a disease that causes extreme hair loss, while some were seeking preventive treatment.
In short, the results have been impressive. Participating clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair. An estimated 80-85% of the males, and more than 90% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. Among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
Although Revive hasn’t been approved for use in the United States, Biologix has reported a substantial uptick in clinician interest internationally. In the two month period between March and April, the company’s worldwide Clinician Licensing Department has contracted on behalf of Biologix with 80 new medical services clinics in 26 new countries, bringing that total to 37. The company also stated that cumulatively, the number of contracted clinics have a patient population in excess of 3 million.
Donna Lieder, Biologix Vice President of Clinician Licensing, stated, “During the recent period we witnessed tremendous increase in interest by the global medical community seeking to become certified Biologix Hair Therapists and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System.” She went on to say that Biologix will continue to actively pursue worldwide marketing opportunities.…
Penny Pick Elite Recent Articles